Gujarat-based Pharma firm Develops Potential Treatment for Diabetic Neuropathy

Asprius Lifesciences, a pharmaceutical company based in Gujarat, has developed a new treatment for diabetic neuropathy, a condition that causes nerve damage in the body's peripheral areas. The treatment, a fixed-dose combination (FDC) of two drugs, has received a patent from the company. Diabetic neuropathy is a common condition that affects more than 2% of the world's population. It is caused by nerve damage in the hands and feet that controls sensation and movement. Diabetic neuropathy symptoms can include numbness, tingling, pain, and weakness in the extremities.

The company is currently conducting clinical trials to assess the FDC's safety and efficacy. If the trials go well, the company intends to launch the treatment in India next year. "We are excited about the potential of this new treatment to help people with diabetic neuropathy," said Asprius Lifesciences Chairman and CEO Vishal Zinzuwadia. "It is high time we addressed this prevalent condition, especially as Diabetic Neuropathy can cause damage to specific subdivisions of the nervous system," said Dr. Sanjay Agrawal, the inventor of this formulation and the company's Medical Director. Diabetic neuropathy is a serious condition with serious consequences for one's quality of life. Asprius Lifesciences' new treatment offers hope to people suffering from this condition, and it may help to improve their symptoms and lower their risk of further complications.